...
首页> 外文期刊>International Journal of Nanomedicine >Cyclosporine A-nanoparticles enhance the therapeutic benefit of adipose tissue- derived stem cell transplantation in a swine myocardial infarction model
【24h】

Cyclosporine A-nanoparticles enhance the therapeutic benefit of adipose tissue- derived stem cell transplantation in a swine myocardial infarction model

机译:环孢素A纳米颗粒增强猪心肌梗死模型中脂肪组织来源的干细胞移植的治疗效果

获取原文
           

摘要

Abstract: Treatment of myocardial infarction (MI) with adipose-derived stem cells (ASCs) has produced promising results. Cyclosporine A (CsA) inhibits apoptosis by preventing the opening of mitochondrial permeability transition pores. A CsA nanoparticle emulsion (CsA-NP) has lower toxicity and higher efficiency as compared to CsA. In this study, we hypothesized that a combination of ASCs and CsA-NP would enhance the therapeutic efficiency in a swine MI model. MI was induced in pig hearts by occlusion of the left anterior descending artery. The animals that survived MI were divided into four groups and 1 week later received intracoronary ASCs (ASCs, n=6), intracoronary culture media in combination with CsA-NP (CsA-NP, n=6), intracoronary ASCs in combination with CsA-NP (ASCs + CsA-NP, n=6), or remained untreated (control, n=4). Animals were sacrificed 8 weeks later and were evaluated for cardiac function by delayed-enhanced magnetic resonance imaging and immunohistopathology. We observed that the left ventricular ejection fraction (LVEF) was significantly increased in the ASCs + CsA-NP group, compared to the CsA-NP group (53.6%±2.4% versus 48.6%±1.5%, P<0.05), and the ASCs group (53.6%±2.4% versus 48.3%±1.8%, P<0.05). More importantly, the infarct size was significantly smaller in the ASCs + CsA-NP group as compared to the CsA-NP group (6.2±1.7 cm3 versus 9.1±3.4 cm3, P<0.05) and the ASCs group (6.2±1.7 cm3 versus 7.5±0.6 cm3, P<0.05). These findings were further confirmed by analysis of the expression of cardiomyocyte markers, myosin heavy chain (α-actinin) and troponin T. In addition, the CsA-NP + ASCs treatment promoted neovascularization (P<0.05) and inhibited cardiomyocyte apoptosis (P<0.01) compared to the control group. This study demonstrates that CsA-NP enhanced the therapeutic benefits of ASCs transplantation for MI.
机译:摘要:用脂肪干细胞(ASCs)治疗心肌梗塞(MI)取得了可喜的结果。环孢菌素A(CsA)通过阻止线粒体通透性转换孔的开放来抑制细胞凋亡。与CsA相比,CsA纳米粒子乳液(CsA-NP)具有更低的毒性和更高的效率。在这项研究中,我们假设ASC和CsA-NP的组合将提高猪MI模型的治疗效率。猪左心前降支闭塞诱发心肌梗死。 MI存活的动物分为四组,并在1周后接受冠状动脉内ASC(ASC,n = 6),冠状动脉内培养基与CsA-NP组合(CsA-NP,n = 6),冠状内ASC与CsA组合-NP(ASCs + CsA-NP,n = 6),或未治疗(对照组,n = 4)。 8周后处死动物,并通过延迟增强的磁共振成像和免疫组织病理学评估其心功能。我们观察到,与CsA-NP组相比,ASCs + CsA-NP组的左心室射血分数(LVEF)显着增加(53.6%±2.4%对48.6%±1.5%,P <0.05),并且ASCs组(53.6%±2.4%对48.3%±1.8%,P <0.05)。更重要的是,与CsA-NP组(6.2±1.7 cm3对9.1±3.4 cm3,P <0.05)和ASCs组(6.2±1.7 cm3对)相比,ASCs + CsA-NP组的梗死面积明显更小7.5±0.6 cm3,P <0.05)。通过分析心肌细胞标志物,肌球蛋白重链(α-actinin)和肌钙蛋白T的表达进一步证实了这些发现。此外,CsA-NP + ASCs治疗可促进新血管形成(P <0.05)并抑制心肌细胞凋亡(P < 0.01)与对照组相比。这项研究表明,CsA-NP增强了ASCs移植对MI的治疗作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号